At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 276 enrolled
Drug / intervention
HSK21542 +1 moredrug
Likely dose
HSK21542 1 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia
In Brief
A Phase 3 clinical trial evaluating HSK21542 and Placebo for Postoperative Analgesia. Completed, enrolled 276 participants across 1 site.
Detailed Summary
This study is a multi-center, randomized, double-blind, placebo-controlled study. A total of 276 subjects undergoing elective laparoscopic surgery under general anesthesia are planned to be enrolled and randomized into 2 groups, i.e., the HSK21542 group (138 subjects) and the placebo group (138 subjects).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Analgesia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMar 2021
Primary CompletionJul 2021
Study CompletionSep 2021
TodayJul 2026
First PostedFeb 4, 2021
Enrollment StartMar 24, 2021
Primary CompletionJul 30, 2021
Study CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago
Interventions
HSK21542drug
HSK21542：1 µg/kg
Placebodrug
Placebo